Opendata, web and dolomites

proLungPlasma

Validation of a Lung Cancer Plasma Reflex Test Using Epigenetic Biomarker for Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "proLungPlasma" data sheet

The following table provides information about the project.

Coordinator
EPIGENOMICS AG 

Organization address
address: KLEINE PRAESIDENTENSTR 1
city: BERLIN
postcode: 10178
website: www.epigenomics.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.epigenomics.com/products/epi-prolung/
 Total cost 2˙772˙527 €
 EC max contribution 2˙772˙527 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EPIGENOMICS AG DE (BERLIN) coordinator 2˙772˙527.00

Map

 Project objective

The objective of “proLungPlasma” is the clinical validation of a lung cancer test, which detects DNA methylation of the specific biomarker mSHOX2. Methylation of DNA is an important epigenetic process involved in fundamental biological processes as development and cell differentiation. Aberrant DNA methylation plays a major role in cancer development. Epigenomics is very successfully engaged in epigenetic research since 1998 resulting in an outstanding proprietary platform for epigenetic biomarker discovery for cancer. Epigenomics is now market leader in epigenetic biomarker test kits detecting most frequently occurring forms of cancer as colorectal and lung cancer from different sample materials. Lung Cancer is the most deadly of all cancer diseases. Unfortunately, lung cancer screening by Low Dose Computer Tomography (LDCT) is burdened by unacceptably high false positive rates. The newly developed Epi proLung Plasma Reflex Assay is urgently required as a tool for reducing false positive rates. Therefore, the Epi proLung Plasma Reflex Assay is a highly anticipated pre-requisite for successful implementation of lung cancer screening in Europe. This business innovation project will validate the Epi proLung Plasma Reflex Assay for the diagnosis of lung cancer in plasma under the upcoming new IVD regulation. The validation process to be performed in this business innovation project will be used as a blueprint for the standardized validation of all further epigenetic biomarker blood tests. Epigenomics’ established test platform, its product development and regulatory expertise, and the standardized validation process are expected to kick-off further strong growth on major global MDx markets.

 Deliverables

List of deliverables.
Registration Documents Documents, reports 2019-05-30 12:55:42

Take a look to the deliverables list in detail:  detailed list of proLungPlasma deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Gunter Weiss, Anne Schlegel, Denise Kottwitz, Thomas König, Reimo Tetzner
Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease
published pages: 77-84, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.08.123
Journal of Thoracic Oncology 12/1 2019-07-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROLUNGPLASMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROLUNGPLASMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More